10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all ...

8 analysts have shared their evaluations of 10x Genomics TXG during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services ...

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in ...

Access NASDAQ:TXG financials, view the annual report and financial statements, including income statement, balance sheet, cash flow.

10x Genomics is down 22.4% since the beginning of the year, and at $11.01 per share, it is trading 53.1% below its 52-week high of $23.49 from August 2024. Investors who bought $1,000 worth of 10x ...

Single-cell RNA-seq (scRNA-seq) has spent the past decade maturing into a foundational technology. Over that time, the ...

Review 10x Genomics Inc Ordinary Shares - Class A (TXG:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.